Physician profile
Malcolm D Carson
NPI 1164925947
$9,100.93
in general payments reported to CMS, 2019-2025
8 companies · $5,752 in 2025
The $5,752 reported for 2025 was more than what 97% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.15 · 2022: $3,174 · 2023: $106 · 2024: $17.11 · 2025: $5,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,275 · Travel and Lodging: $1,097 · Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,275.00 |
| Travel and Lodging | $1,096.52 |
| Food and Beverage | $503.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,309.36 | 2022-2025 | Botox |
| Allergan, INC. | $1,604.33 | 2021-2022 | |
| Medtronic, INC. | $66.47 | 2022-2023 | Intellis Adaptivestim |
| Argenx US, INC. | $28.27 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $26.03 | 2023 | Ingrezza |
| Biogen, INC. | $25.56 | 2025 | Skyclarys |
| Mdd US Operations, LLC | $23.80 | 2025 | Qelbree |
| Amneal Pharmaceuticals LLC | $17.11 | 2024 | Rytary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.